IMBiologics

Name

IMBiologics

Legal name

아이엠바이오로직스

Website

https://imbiologics.com

Company type

Public

Founded year

2020

Operating status

Ipo

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Bispecific antibody therapeutics
• Autoimmune disease drugs
• Immuno-oncology treatments
• Antibody drug conjugates
• Technology out-licensing

Headquarters

HQ city

Suwon

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Technology Licensing / Out-licensing: IMBiologics develops antibody therapeutics through preclinical and early clinical stages, then out-licenses to global pharmaceutical companies for late-stage development and commercialization. The company has secured major deals including $940M+ with Navigator Medicine (June 2024) and $320M with Huadong Pharma (August 2024) for IMB-101 and IMB-102.
2. IPO Proceeds for R&D: Listed on KOSDAQ on March 20, 2026, raising 52 billion KRW (~$35.09M USD). Proceeds of 37 billion KRW earmarked for accelerating non-clinical development of IMB-201 and IMB-402.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

IMBiologics is a biotechnology company that discovers and develops immunomodulatory antibody drug candidates for autoimmune diseases (hidradenitis suppurativa, atopic dermatitis, rheumatoid arthritis) and immuno-oncology. The company uses its proprietary IM-OpDECon platform to design bispecific antibodies, develops candidates through preclinical and early clinical stages, and then out-licenses the assets to global pharmaceutical partners for late-stage development and commercialization, generating revenue through upfront payments, milestones, and royalties.

Product overview

IMBiologics is an antibody drug development company founded in August 2020, developing treatments in autoimmune diseases and immuno-oncology fields. The company operates two core platforms: IM-OpDECon (optimal antibody modality creation technology) and IgM platform. The product portfolio includes lead asset IMB-101 (OX40L/TNF-α bispecific antibody, licensed globally), IMB-102 (OX40L bispecific for atopic dermatitis), IMB-106 (autoimmune, targeted for 2026 out-licensing), IMB-201A/B (HLA-G targeting ADC and tri-specific for oncology), IMB-202 (CD40 agonist), and the ePENDY half-life extension platform for macular degeneration. The company listed on KOSDAQ in March 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• IMB-101 OX40L/TNF-α bispecific antibody for autoimmune diseases with IV and subcutaneous (SC) formulations. Lead indication is hidradenitis suppurativa (HS); additional indications include atopic dermatitis and rheumatoid arthritis. Licensed globally to Navigator Medicine (US) and Huadong Pharma (China) with combined deal value of 1.8 trillion KRW.
• IMB-102 OX40L-based bispecific antibody for atopic dermatitis treatment. Currently in preclinical stage with Phase 1 trial entry planned for 2027. Animal model demonstrated 31% disease reduction at week 2 versus Sanofi's Amarx at 13%.
• IMB-106 Autoimmune disease treatment candidate targeting long-lasting efficacy through improved dosing convenience. Currently in development with animal proof-of-concept completed; targeted for technology transfer in 2026.
• IMB-201A

Quantifiable outcome

• IMB-101 Phase 1a TRAE 3.3% vs Sanofi Bibecvimab's 13.3% (Phase 1)
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• Miravo BiotechnologycoreTechnology or Integration · 19 March 2026Strategic cooperation and partnership for AI-driven drug discovery focusing on next-generation antibody pipeline development. IMBiologics combines its full-cycle drug development capabilities with Miravo's AI protein engineering platform to enhance research efficiency and strengthen global market competitiveness.
• Huadong Pharma (화동제약)coreStrategic or Co-development Partner · 1 August 2024Global technology transfer deal worth approximately $320M for IMB-101, expanding the licensing territory in Greater China region.
• Navigator MedicineflagshipStrategic or Co-development Partner · 1 June 2024Global technology transfer deal worth approximately $940M for IMB-101 (development code NAV-240). Navigator Medicine is leading Phase 2 clinical development of IMB-101 globally for hidradenitis suppurativa and other inflammatory diseases. Navigator Medicine is a NewCo model established by RA Capital and Forbion with big pharma deal-making experience.
• AstraZenecaminorStrategic or Co-development PartnerThrough KHIDI's Project NOVA, IMBiologics participated in partnering sessions with AstraZeneca experts at the BIO International Convention in San Diego. Companies specializing in immunology, oncology, and nephrology and metabolic diseases presented technologies to AstraZeneca for evaluation as part of Korea's open innovation strategy.
• Korea Drug Development Fund (KDDF)coreStrategic or Co-development PartnerKDDF has been a key supporter of IMBiologics, which was selected as a KDDF-supported project for its OX40LxTNFα bispecific antibody program. KDDF is also recognized for supporting IMB-101's global technology transfer to Johnson & Johnson Innovative Medicine (via LigaChem Biosciences) for LCB84 TROP2 ADC worth 2.25 trillion KRW.
• Donga-A ST (동아ST)minorStrategic or Co-development PartnerMOU signed for 'IgM platform' drug discovery collaboration.
• National New Drug Development Program (국가신약개발사업단)minorStrategic or Co-development PartnerIMBiologics participated in and presented at the 2023 National New Drug Development Program R&D Workshop, presenting research findings as part of the program's ecosystem.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• LigaChem Biosciences: Korean biotech developing antibody-drug conjugates and innovative therapeutics. Comparable to IMBiologics as a Korean innovative biologics developer pursuing global pharma out-licensing deals (e.g., TROP2 ADC partnership with Johnson & Johnson).
• Genmab: Pioneer in bispecific antibody technology with proprietary DuoBody platform. Directly comparable to IMBiologics' IM-OpDECon platform approach and pipeline of bispecific antibodies targeting immunology and oncology indications.
• MacroGenics: Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer and autoimmune diseases. Closely comparable pipeline strategy to IMBiologics, including DART platform technology for multi-specific antibodies.
• Akeso: Chinese biotech with deep bispecific antibody pipeline (e.g., cadonilimab, ivonescimab) targeting oncology and autoimmune indications. Comparable multi-modality bispecific strategy and emerging global pharma partnership model.
• Junshi Biosciences: Chinese-listed biotech developing innovative bispecific antibodies and immuno-oncology therapeutics. Comparable out-licensing and co-development model with global pharma partners for innovative biologics targeting cancer and autoimmune diseases.

Broad incumbents

• Sanofi: Global pharmaceutical company developing Bibecvimab, a direct competitor to IMBiologics' IMB-101 in the OX40L/TNF-α bispecific space. Established player in immunology (Dupixent) and immuno-oncology with global commercialization reach.
• Daiichi Sankyo: Global leader in antibody-drug conjugate (ADC) technology with Enhertu franchise. Comparable to IMBiologics' IMB-201A HLA-G ADC program and provides a benchmark for ADC platform economics and global partnership structures.

Emerging players

• Adagene: Clinical-stage biotech using AI-powered antibody discovery and engineering platform to develop bispecific and conditionally activated antibodies. Comparable to IMBiologics' AI-augmented antibody discovery approach via Miravo partnership.
• Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for oncology with proprietary technology platform. Comparable to IMBiologics in pipeline approach focusing on novel multi-specific antibody formats targeting immunology and immuno-oncology.

Regional players

• HK inno.N: Korean pharmaceutical company that originally developed the OX40L/TNF-α antibody technology acquired by IMBiologics in November 2020. Strategic technology origin partner and comparable Korean biotech transitioning toward innovative biologics development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMBiologics